CD13: A Key Player in Multidrug Resistance in Cancer Chemotherapy

Oncol Res. 2020 Dec 10;28(5):533-540. doi: 10.3727/096504020X15919605976853. Epub 2020 Jun 12.

Abstract

Cancer is one of the most serious diseases that are harmful to human health. Systemic chemotherapy is an optimal therapeutic strategy for the treatment of cancer, but great difficulty has been encountered in its administration in the form of multidrug resistance (MDR). As an enzyme on the outer cell surface, CD13 is documented to be involved in the MDR development of tumor cells. In this review, we will focus on the role of CD13 in MDR generation based on the current evidence.

Publication types

  • Review

MeSH terms

  • Apoptosis
  • CD13 Antigens / metabolism*
  • Drug Resistance, Multiple*
  • Drug Resistance, Neoplasm*
  • Humans
  • Multidrug Resistance-Associated Proteins / metabolism
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism
  • Neoplastic Stem Cells / metabolism
  • Oxidative Stress
  • Reactive Oxygen Species

Substances

  • Multidrug Resistance-Associated Proteins
  • Reactive Oxygen Species
  • CD13 Antigens